Category:
Medical Studies
19th Annual Miami Brest Cancer Conference
What is the optimal local and systemic therapy for DCIS? Do all DCIS patients need radiation therapy? What is the optimal endocrine therapy for DCIS?
|
2001 |
Category:
Medical Studies
Lymphatic Mapping in DCIS
The appropriateness of sentinel lymph node biopsy in the management of patients with biopsy diagnoses of ductal carcinoma in situ (DCIS) or DCIS with microinvasion (DCISM) has not been established.
|
2002/05/01 |
Category:
Definition & Diagnosis
DCIS: A breast cancer dilemma
When a woman hears "breast cancer," no matter how small or treatable her disease, the words pack a wallop. Last year, a biopsy revealed that Lois Tibbetts, a 52-year-old woman from Scituate, Mass., had a form of breast cancer called ductal carcinoma in situ, or DCIS. It is a very early form of breast cancer confined to the milk ducts in which it formed. With proper treatment, the chances of curing DCIS are nearly 100 percent. Still, Tibbetts panicked.
"It's scary when you hear the word 'cancer'," she says. A close friend of hers had died of breast cancer at age 47. "I remember thinking, 'I'm not going to make it. I'm going to be a statistic.'"
|
2002/08 |
Category:
Medical Studies
Timing of Chemotherapy Improves Survival in Breast Cancer
NEW YORK, December 12, 2002 -- New research shows that giving doses of chemotherapy more frequently in time, leads to a significant improvement in survival with no increase in toxicity in women with node-positive breast cancer.
|
2002/12/02 |
Category:
Medical Studies
Sentinel Lymph Node Biopsy: Questions and Answers
A sentinel lymph node (SLN) is the first lymph node(s) to which cancer cells are likely to spread from the primary tumor. Cancer cells may appear in the sentinel node before spreading to other lymph nodes (see Question 2).
SLN biopsy can be used to help determine the extent or stage of cancer (see Question 3).
|
2003-2004 various |
Category:
Medical Studies
Micrometastases in Sentinel Lymph Node Biopsies: The Medical Oncologist's Perspective: To Treat or N
Based on present data, isolated cancer cells or small clusters should be disregarded when making recommendations about adjuvant systemic therapy.
|
2003/01/10 |
Category:
Medical Studies
Aromatase Inhibitors in Breast Cancer: An Update
Background: Tamoxifen has been the endocrine treatment of choice for patients with breast cancer. The development of selective aromatase inhibitors has offered an alternative management approach for patients in whom a hormonal approach is indicated.
*Registration Required, Free*
|
2003/02/10 |
Category:
Medical Studies
DCIS breast cancer: radiotherapy can reduce recurrence risk
25 July 2003
New recommendations on the clinical management of ductal carcinoma in situ (DCIS) of the breast will emphasise the value of radiotherapy after initial surgical excision, the National Breast Cancer Centre (NBCC) says.
(Ductal carcinoma in situ (DCIS) is a cancer inside the ducts of the breast that has not grown through the wall of the duct into the surrounding breast tissues. It is sometimes referred to as a precancer, and is detected increasingly as a consequence of mammogram screening programmes.)
The advice followed several large international studies demonstrating that radiotherapy reduced the risk of recurrent DCIS and invasive cancer after surgery, said leading breast surgeon Professor Colin Furnival, chair of the NBCC working party on DCIS.
The latest study of nearly 1700 women in Australia, New Zealand and the UK showed that the rate of DCIS recurrence was lower in patients who received radiotherapy, compared with those who did not, with radiotherapy associated with an 8.9 per cent reduction in absolute risk (Lancet 2003; 362: 95-102).
|
2003/07 |
Category:
Miscellaneous
San Antonio Breast Cancer Symposium
Site Home Free Registration -- The Abstracts2View™-on-Line program is supported by an unrestricted grant from GlaxoSmithKline.
|
2003/12 |
Category:
Definition & Diagnosis
New Test to Help Women with Early Stage Breast Cancer Make Treatment Choices
Researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health reported that a new genetic test can help predict the likelihood that a breast cancer will recur, and, in turn, whether chemotherapy is necessary.
Oncologists currently use a woman's age, tumor size, tumor grade, and estrogen receptor status to assess her risk for distant recurrence (metastasis). But it is still a "best guess" scenario - we don't have a perfect way of determining who will benefit from chemo and who doesn't really need it.
Genomic Health developed the new genetic test by analyzing tumor samples from nearly 700 women who had been involved in a 1980s NSABP study. The analysis identified 21 genes that appeared to be related to a breast cancer recurrence.
|
2003/12 |
Category:
Medical Studies
An interim analysis of a prospective multi-institutional cohort study: quantitative real-time RT-PCR
The clinical relevance of molecular detection of micrometastatic breast cancer in sentinel and axillary lymph nodes has not been established.
|
2003/12/03 |
Category:
Medical Studies
Micrometastases in sentinel lymph nodes of patients with ductal carcinoma in situ of the breast have
Background: (Micro-)metastases may be detected in sentinel axillary lymph nodes of patients with in situ carcinoma or small invasive carcinomas of the breast. For some surgeons this is a reason to routinely perform a sentinel node procedure in situations otherwise known to have an excellent prognosis without axillary staging. The incidence and predictive value of these positive nodes is uncertain.
|
2003/12/03 |
Category:
Medical Studies
Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial acc
Background: The ATAC trial randomized 9366 postmenopausal women with early breast cancer to 5 years of treatment with anastrozole (A) or tamoxifen (T) or the combination (C) of A+T. After 47 months median follow-up the hazard ratio (HR) for disease-free survival was 0.86 (0.760.99, p=0.03) in the overall population and 0.82 (0.700.96, p=0.014) in the estrogen receptor (ER) and/or progesterone receptor (PgR) positive group, in favor of A when compared with T.
|
2003/12/03 |
Category:
Medical Studies
Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen
Background: The ATAC trial showed that anastrozole (‘Arimidex’; A) has superior efficacy to tamoxifen (T) as adjuvant therapy in early hormone receptor-positive breast cancer.
|
2003/12/03 |
Category:
Medical Studies
Resistance to endocrine therapy in a xenograft model of HER-2 overexpressing breast cancer is accomp
Breast cancer growth is regulated by estrogen and other steroid hormones as well as peptide growth factors such as EGF and IGF-1. Crosstalk between these signaling pathways may determine patterns of response and resistance to endocrine therapy.
|
2003/12/03 |
Category:
Medical Studies
A retrospective review of wide excision alone for ductal carcinoma in situ (DCIS) of the breast
Background: The standard treatment for ductal carcinoma in situ (DCIS) of the breast today is wide excision (WE) followed by radiotherapy.
|
2004/07/15 |
Category:
Medical Studies
Mammographic Predictors of the Presence and Size of Invasive Carcinomas Associated With Malignant Mi
Our objective was to determine the degree with which mammographic features predict the presence and size of invasive carcinomas associated with malignant mammographic microcalcification lesions without a mass.
|
2004/10/01 |
Category:
Definition & Diagnosis
Ductal Carcinoma in Situ (DCIS)
The American Cancer Society estimates that 41,000 news cases of ductal carcinoma in situ (also called DCIS or intraductal carcinoma) will be diagnosed in 2000, making DCIS the most common type of non-invasive breast cancer in women. DCIS accounts for nearly 25% of all breast cancer diagnoses.
|
2005 |
Category:
Definition & Diagnosis
Staging and Survival Rates of Breast Cancer
What is Staging?
Staging is the process physicians use to assess the size and location of a patient’s cancer. Identifying the cancer stage is one of the most important factors in selecting treatment options.
|
2005 |
Category:
Medical Studies
Chemotherapy and Tamoxifen for Early-Stage Disease
Is this for me? If you want to know if the long-term benefits of chemotherapy or tamoxifen are worth the side effects, you might want to read this article.
|
2005/05/14 |